Tugizova Madina, Vlahovic Luka, Tomczak Anna, Wetzel Nora Sandrine, Han May Htwe
Department of Neurology, Division of Neuroimmunology, Stanford University, 1201 Welch Road, MSLS p212, Stanford, CA 94305 USA.
Multiple Sclerosis Center, Stanford Hospital and Clinics, Palo Alto, CA USA.
Curr Treat Options Neurol. 2021;23(4):13. doi: 10.1007/s11940-021-00667-3. Epub 2021 Mar 30.
This review discusses the current treatment trends and emerging therapeutic landscape for patients with neuromyelitis optica spectrum disorder (NMOSD).
Conventional immune suppressive therapies, such as B cell depletion, have been used for long-term treatment. However, the availability of recent FDA-approved and investigational drugs has made therapeutic choices for NMOSD more complex.
Recent randomized clinical trials have shown that eculizumab, inebilizumab, and satralizumab are efficacious therapies for AQP4 seropositive NMOSD. These therapies may not have the same benefit in patients with seronegative NMOSD, including MOG-associated disease, and further investigation is required in this population. Reliable biomarkers to guide therapy decisions are urgently needed. There is a plethora of promising investigational therapies currently in the pipeline with exciting and novel mechanisms of action.
本综述讨论视神经脊髓炎谱系障碍（NMOSD）患者的当前治疗趋势和新兴治疗前景。
传统免疫抑制疗法，如B细胞清除，已用于长期治疗。然而，近期美国食品药品监督管理局（FDA）批准的药物和正在研究的药物，使得NMOSD的治疗选择更加复杂。
近期随机临床试验表明，依库珠单抗、inebilizumab和萨特利珠单抗是AQP4血清阳性NMOSD的有效疗法。这些疗法对血清阴性NMOSD患者（包括MOG相关疾病）可能没有同样的益处，该人群需要进一步研究。迫切需要可靠的生物标志物来指导治疗决策。目前有大量有前景的研究性疗法正在研发中，其作用机制令人兴奋且新颖。
